Tiffany A. Traina, MD
The treatment landscape of HER2-postive breast cancer went through an exponential shift in 2017 with 2 new FDA approvals and the emergence of encouraging novel therapeutic options.
, Traina, a medical oncologist at Memorial Sloan Kettering Cancer Center, discussed her experiences with using neratinib and pertuzumab, and shared her excitement on the direction in which the HER2-positive breast cancer field is moving.
OncLive: Can you discuss the trepidation that we are seeing with neratinib?
Neratinib’s approval is for an extended adjuvant scenario for HER2-positive early-stage breast cancer. It’s in a unique position because so much has evolved in the treatment of HER2-positive early-stage disease. We now have much more use of neoadjuvant pertuzumab in combination with trastuzumab and an anthracycline-taxane–based neoadjuvant regimen. We recently saw the data from the APHINITY trial showing that 1 full year of adjuvant trastuzumab and pertuzumab was associated with improved survival outcomes. Now trying to integrate the FDA approval of neratinib is just a bit more challenging. The early trials with neratinib did not have patients who had prior exposure to pertuzumab. Therefore, I am not quite sure where its place will be.
... to read the full story